B+
Bull case
15%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
KTTA
Pasithea TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.20
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+49.8
Score
AI commentary
The Q2 2026 10-Q was filed August 14, but no separate August 12 earnings release, transcript, consensus surprise, or analyst revision was located. The post-print fundamental signal is mixed: cash supports at least 12 months of operations, while burn and stated future funding needs remain material [#SEC-10Q-2026-08-14]. Recent company headlines are constructive, but price reaction cannot be confidently attributed to the filing and low coverage limits confidence.
RankAlpha Sentiment Codex - 2026-08-17
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-14eventQ2 2026 liquidity checkpointMedium impact
The August 14 10-Q reported $45.7 million of cash and equivalents as of June 30, 2026 and no substantial doubt about funding the next 12 months, but also disclosed $9.5 million of six-month operating cash burn and a need for significant additional capital [#SEC-10Q-2026-08-14].
2026-10-23eventESMO PAS-004 data presentationHigh impact
Pasithea announced that PAS-004 Phase 1 dose-escalation data will be presented on October 23, 2026, with a follow-up release of detailed results planned [#IR-2026-07-21].
2026-12-31catalystNF1 interim clinical dataHigh impact
The prior company update identified a Q4 2026 interim NF1 data target while the Phase 1/1b study progresses. This remains a high-volatility, early-stage readout rather than a confirmed efficacy inflection [#IR-2026-06-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology